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Surrogate endpoints are very important in regulatory decision making in
healthcare, in particular if they can be measured early compared to the
long-term final clinical outcome and act as good predictors of clinical benefit.
Bivariate meta-analysis methods can be used to evaluate surrogate endpoints
and to predict the treatment effect on the final outcome from the treatment effect
measured on a surrogate endpoint. However, candidate surrogate endpoints are
often imperfect, and the level of association between the treatment effects on
the surrogate and final outcomes may vary between treatments. This imposes
a limitation on methods which do not differentiate between the treatments.
We develop bivariate network meta-analysis (bvNMA) methods, which com-
bine data on treatment effects on the surrogate and final outcomes, from trials
investigating multiple treatment contrasts. The bvNMA methods estimate the
effects on both outcomes for all treatment contrasts individually in a single anal-
ysis. At the same time, they allow us to model the trial-level surrogacy patterns
within each treatment contrast and treatment-level surrogacy, thus enabling
predictions of the treatment effect on the final outcome either for a new study
in a new population or for a new treatment. Modelling assumptions about the
between-studies heterogeneity and the network consistency, and their impact
on predictions, are investigated using an illustrative example in advanced col-
orectal cancer and in a simulation study. When the strength of the surrogate
relationships varies across treatment contrasts, bvNMA has the advantage of
identifying treatment comparisons for which surrogacy holds, thus leading to
better predictions.
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1 INTRODUCTION
Surrogate endpoints are very important in the drug development process, at both the trial design and the evaluation stage.
They are particularly useful when they can provide early measurement of the treatment effect, in settings where a long
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follow-up time is required before measurement of the final clinical outcome.1 This is often the case in cancer where over-
all survival is of primary interest whilst other outcomes such as progression-free survival (PFS) potentially can be used
to measure the effect of a treatment earlier. Alternatively, PFS may be of primary interest and tumour response (TR) is
then investigated as a short term surrogate endpoint to PFS. Before they can be used in evaluation of new health tech-
nologies, candidate surrogate endpoints have to be assessed for their predictive value of the treatment effect on the final
clinical outcome. Surrogate outcomes are validated by estimating the pattern of association between the treatment effects
on surrogate and final endpoints across trials, in different populations and/or investigating different treatments, using
meta-analytic techniques.2-7
Multivariate meta-analysis methods are used to obtain average treatment effects on multiple endpoints while taking
account of the correlations between them8-11 and, as such, are suitable tools formodelling surrogate endpoints.6,7 Bivariate
meta-analysis of treatment effects on a surrogate and a final outcome allows for both the validation of a surrogate endpoint
and for making predictions of an unobserved treatment effect on the final clinical outcome from observed treatment
effects on a surrogate endpoint.
Candidate surrogate endpoints often are not perfect, and the association patterns between the treatment effects on
the surrogate and final outcomes may vary between treatments. Whilst bivariate meta-analysis, described in detail in
Section 3, can be used to model surrogate endpoints, it does not differentiate between the treatment options. Network
meta-analysis (NMA) combines data from trials investigating heterogeneous treatment contrasts and has the advantage
of estimating effects for all treatment contrasts individually. At the same time, the consistency assumption allows for
combining evidence (and borrowing strength) across the treatment contrasts. In this paper, wewill exploit this framework
to model surrogacy relationships by building on the previously reported methods of multivariate NMA (mvNMA).12-16
In themvNMA, true treatment effects onmultiple correlated outcomes are assumed to follow separate multivariate dis-
tributions for each treatment contrast. The previously reportedmvNMAmethods typically simplified the between-studies
variance-covariance structures by assuming homogeneity of the correlations and the heterogeneity parameters across
treatment contrasts. We relax this assumption of homogeneity to model in detail different association patterns between
the effects on surrogate and final endpoints separately for different treatments or treatment classes. By allowing such pat-
terns to differ across treatments, the methodology can help to identify treatments for which the surrogacy holds and to
improve predictions. The network consistency assumption provides a framework for combining evidence across a range
of treatment contrasts and hence modelling and distinguishing surrogacy patterns at the study level (within each treat-
ment contrast) and at the treatment contrast level. These two levels of surrogacy enable predictions of the treatment effect
on the final outcome in a new study investigating either an existing treatment in a new population (study-level surrogacy
within a treatment contrast) or a new treatment (treatment-level surrogacy). We extend the second-order consistency
condition, described by Lu and Ades17 in a univariate NMA, to the bivariate case, in order to gain additional precision in
modelling surrogate relationships.
We illustrate the use of the methods in an example in advanced colorectal cancer (aCRC) introduced in Section 2,
describe the methods in Sections 3 and 4, and present the results of fitting the methods to data from the illustrative
example in Section 5. To illustrate themotivation and the application of themethodology in amore detailed and controlled
manner as well as to compare the performance of the methods, we carried out a simulation study presented in Section 6.
We conclude this paper with a discussion in Section 7. We fit all models in a Bayesian framework using the OpenBUGS
software.
2 ILLUSTRATIVE EXAMPLE
We use data from randomised controlled trials (RCTs) in aCRC, investigating a range of different treatment options,
to illustrate how the hierarchical bivariate NMA (bvNMA) models, proposed in this paper, can differentiate the asso-
ciation patterns between the treatment contrasts or classes whilst borrowing strength across treatment contrasts. Data
were obtained from four published systematic reviews of RCTs investigating pharmacological treatments in aCRC, cat-
egorised into classes with respect to their mechanism of action. These were targeted therapies including antiangiogenic
treatments targeting vascular endothelial growth factor (anti-VEGF),18 anti epidermal growth factor receptor inhibitors
(EGFRis),19 humanised monoclonal antibody targeting integrin receptors, and monoclonal antibody targeting the type 1
insulin-like growth factor receptor20 or chemotherapies compared to the targeted therapies20,21 and combinations of these
therapies. Fifteen RCTs investigated use of anti-VEGF with chemotherapy vs. chemotherapy alone, 24 RCTs of EGFRi
with chemotherapy vs. chemotherapy alone, 4 RCTs of EGFRi with chemotherapy vs. anti-VEGF with chemotherapy,
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FIGURE 1 Scatter plot and network diagram for the advanced colorectal cancer example. A, Chemotherapy alone; B, Antiangiogenic
treatments targeting vascular endothelial growth factor (anti-VEGF) therapies + chemotherapy; C, Epidermal growth factor receptor
inhibitor (EGFRi) + chemotherapy; D, EGFRi + anti-VEGF therapies + chemotherapy; E, antibody targeting the type 1 insulin-like growth
factor receptor; F, antibody targeting integrin receptor + chemotherapy. HR, hazard ratio; OR, odds ratio; PFS, progression-free survival;
TR, tumour response [Colour figure can be viewed at wileyonlinelibrary.com]
4 RCTs of EGFRi with anti-VEGF and chemotherapy vs. anti-VEGF with chemotherapy, one study (in two subgroups of
population) of antibody targeting integrin receptor with EGFRi and chemotherapy vs. EGFRi with chemotherapy, one
study of antibody targeting the type 1 insulin-like growth factor receptor with chemotherapy vs. chemotherapy alone, and
one of EGFRi with anti-VEGF and chemotherapy vs. chemotherapy alone. The treatments are summarised in the net-
work diagram of Figure 1 and the data from the individual studies are included in the Supplementary Materials. Tumour
response is used as an example of a potential surrogate endpoint to PFS as a final clinical outcome. Themodels are applied
to data representing treatment effect on the two outcomes on log odds ratio scale for TR and log hazard ratio scale for
PFS. The scatter plot in Figure 1 illustrates the association patterns between the treatment effects on the two outcomes
for each treatment contrast. The within-study correlation between the treatment effects on TR and PFS, required to pop-
ulate the following bivariate meta-analytic models, was obtained from individual participant data of a RCT comparing
Bevacizumab (anti-VEGF) with chemotherapy vs. chemotherapy alone, as reported by Elia et al22 with further details
included in the Supplementary Materials. This correlation was assumed to apply to all studies.
3 BIVARIATE RANDOM EFFECTS META-ANALYSIS
The bivariate random effects meta-analysis (BRMA) model for correlated and normally distributed treatment effects on
two outcomes Y1i and Y2i is usually presented in the form described by Van Houwelingen et al8 and Riley et al9(
Y1i
Y2i
)
∼ N
{(
𝜇1i
𝜇2i
)
,𝚺i
}
, 𝚺i =
(
𝜎21i 𝜎1i𝜎2i𝜌wi
𝜎1i𝜎2i𝜌wi 𝜎
2
2i
)
(1)(
𝜇1i
𝜇2i
)
∼ N
{(
𝛽1
𝛽2
)
,T
}
, T =
(
𝜏21 𝜏1𝜏2𝜌
𝜏1𝜏2𝜌 𝜏
2
2
)
. (2)
In this model, the treatment effects on the surrogate endpoint Y1i and on the final outcome Y2i are assumed to estimate
the correlated true effects 𝜇1i and 𝜇2i with corresponding within-study variances 𝜎21i and 𝜎
2
2i of the estimates and the
within-study correlation 𝜌wi between them. In this hierarchical framework, these true study-level effects follow a bivariate
normal distribution with means (𝛽1, 𝛽2) corresponding to the two outcomes, between-studies variances 𝜏21 and 𝜏22 and a
between-studies correlation 𝜌. Equation (1) represents the within-study model and (2) is the between-studies model.
The elements of the within-study covariance matrix Σi are assumed to be known. Whilst the estimates of the variances
are easily obtained by taking the square of the standard error for each outcome, the estimates of the within-study correla-
tions between the treatment effects on the two outcomes are more difficult to obtain as they would not be reported in the
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original articles. When individual participant data (IPD) are available, the correlation can be obtained by bootstrapping2
or alternatively by fitting a regression model for the two outcomes with correlated errors.23 When IPD are available only
for one study, the correlations (but not the variances or covariances) can be assumed the same for all other studies. In the
absence of IPD, a range of values (between −1 and 1) can be investigated in a sensitivity analysis. Moreover, an alterna-
tive approach was proposed by Wei and Higgins who derived formulae expressing the within-study correlations between
the treatment effects (such as log odds ratios) on the two outcomes in terms of more likely reported correlations between
other measures (such as probabilities of events on the two outcomes for binomial data).24 In the Bayesian framework,
prior distributions can be placed on the within-study correlations. Informative prior distributions for the correlations can
be constructed, eg, by a double bootstrap approach, which results in the correlations being obtained with uncertainty.11
To implement the model in the Bayesian framework, prior distributions are placed on the mean effects, eg, vague prior
distributions 𝛽1 ∼ N(0, 104), 𝛽2 ∼ N(0, 104) and on the between-studies variances and correlation. In the general case, for
any number of outcomes, a prior distribution has to be placed on the whole variance-covariance matrix or the correla-
tion matrix in such a way to ensure that the variance-covariance matrix is positive semi-definite. This can be achieved by
placing an inverse Wishart prior distribution on the variance-covariance matrix10 or by using a separation strategy, with
spherical10,17 or Cholesky decomposition10 of the correlation matrix. Alternatively, a product normal formulation of the
between-studies model can be used where the model is parameterised in the form of a series of univariate conditional
distributions, ensuring that the relationships between the parameters of the model (regression coefficients and condi-
tional variances) and the elements of the between-studies variance-covariance matrix result in the positive semidefinite
between-studies variance-covariance matrix.6,7,11
In the bivariate case, such as considered here, positive semidefiniteness can be achieved by placing prior distributions
on the variances, which are restricted to plausible positive values, eg, by placing uniform prior distributions on the cor-
responding standard deviations 𝜏 j ∼ U(0, 2), and by choosing a prior distribution for the correlation which restricts it to
values between −1 and +1. Here, we use a beta distribution to construct such a prior 𝜌+12 ∼ Beta(1.5, 1.5), as in the work
of Burke et al,25 with details also in the Supplementary Materials.
4 BIVARIATE NMA
The BRMAmodel is typically used to obtain average effects on two correlated outcomes, for studies of the same treatment
or treatment class. In the context of surrogate endpoints, data on a range of treatments are typically used. The BRMA
assumes exchangeability of the treatment effects from all studies regardless of the treatment contrast, by assuming that the
true effects follow a common (here bivariate normal) distribution (as in Equation (2)). This model works well for strong
surrogate relationships across all treatments. However, the association pattern between treatment effectsmeasured on the
surrogate and final outcomes may depend on the treatment contrast. Network meta-analysis can differentiate between
treatment contrasts and in bivariate form can be applied tomodelling such surrogate relationshipswithin and across treat-
ment contrasts. We first discuss general bvNMAmodels in Section 4.1, which describe the study-level (within-treatment)
surrogate relationships in the network. In Section 4.2, we extend thesemodels to allow for an additional level of surrogacy
at the treatment level.
4.1 General bvNMAmodels
4.1.1 Model 1a: bvNMA
Tomodel correlated treatment effects on a surrogate endpoint and a final outcome for which the correlation varies accord-
ing to the treatment contrasts, the assumption made by BRMA, that the true effects follow a common distribution, can
be replaced by an assumption that the true effects corresponding to different treatment contrasts follow separate dis-
tributions. This naturally leads to relaxing the assumption of homogeneity of the between-studies covariance matrix,
allowing its elements (the between-studies correlations 𝜌1kl,2kl between the treatment effects l vs. k on the surrogate (1) and
final (2) outcomes and the heterogeneity parameters for the treatment effects on the two outcomes 𝜏21kl and 𝜏
2
2kl) to vary
across the treatment contrasts kl.
To take into account the network structure of the data, we model the treatment effect differences Yjkli between
treatments k and l in study i for outcome j = 1, 2, as follows:(
Y1kli
Y2kli
)
∼ N
{(
𝜇1kli
𝜇2kli
)
,𝚺i
}
, 𝚺i =
(
𝜎21kli 𝜎1kli𝜎2kli𝜌wkli
𝜎1kli𝜎2kli𝜌wkli 𝜎
2
2kli
)
(3)
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(
𝜇1kli
𝜇2kli
)
∼ N
{(
d1kl
d2kl
)
,
(
𝜏21kl 𝜏1kl𝜏2kl𝜌1kl,2kl
𝜏1kl𝜏2kl𝜌1kl,2kl 𝜏
2
2kl
)}
, (4)
where k and l denote baseline (control) and experimental treatments, respectively, in a study i, 𝜇jkli denote the random
true treatment effects (differences between the effects of treatments k and l) on outcome j in study i, and the djkl are
mean treatment effect differences between treatments k and l for each outcome j. We use the first-order consistency
assumption, as described by Lu and Ades,17 extended here to the bivariate case. For any three treatments (b, k, l), the
treatment differences (𝜇jkli) satisfy the following transitivity relations:(
𝜇1kli
𝜇2kli
)
=
(
𝜇1bli − 𝜇1bki
𝜇2bli − 𝜇2bki
)
. (5)
Taking the expectation of the transitivity equations gives the consistency equations for the first-order moments(
d1kl
d2kl
)
=
(
d1bl − d1bk
d2bl − d2bk,
)
(6)
which represent the relationships between the treatment contrasts in the population.When b = 1 is a common reference
treatment in the network, the treatment effects of each treatment k relative to this common reference treatment 1; the
dj1k are referred to as basic parameters for each outcome j, with dj11 = 0 and the others are given prior distributions
d𝑗1k ∼ N(0, 103). (7)
Prior distributions are also placed on the elements of the between-studies variance-covariance matrices. As in BRMA,
prior distributions for the heterogeneity parameters are selected to ensure that they are restricted to plausible positive
values, such as 𝜏 jkl ∼ unif(0, 2) and for the correlations to ensure restriction to the values between −1 and 1, eg, 𝜌kl+12 ∼
Beta(1.5, 1.5), thus guaranteeing that the variance-covariance matrix for each treatment contrast is positive semidefinite.
The aforementioned model is a simplified bivariate and two-arm study version of the mvNMA multi-arm model by
Achana et al,12 with the exception of retaining the heterogeneous between-studies correlations and variances across con-
trasts (Achana et al introduced a general mvNMAmodel but then simplify it by assuming homogeneous between-studies
covariances, whilst in our model, those heterogeneous parameters are of interest). It is also a simpler version of the
mvNMAmodel by Hong et al,15 however differently implemented, with random effects here being the relative effects for
actual contrasts in each study rather than the effects of each treatments relative to the common baseline.
4.1.2 Model 1b: bvNMAwith second-order consistency
The aforementioned meta-analytic model 1a assumes consistency of treatment effects on both outcomes. The idea of
consistency also implies some constraints on the between-studies variance-covariance matrices, which can be explicitly
introduced to the bvNMAmodel (3) and (4) by assuming the consistency of the second-order moments.
To allow for the second-order consistency, we develop model 1a further. This new model differs from previously devel-
oped mvNMA models in a number of ways. For example, Hong et al showed that, in their contrast-based mvNMA, the
second-order consistency assumption was satisfied for each outcome individually.15 In contrast to this, we investigate
bivariate second-order consistency by deriving the relationships between the covariances for any three treatments (b, k, l)
in the network. In addition, unlike in the models onmulti-arm trials such as by Achana et al12 or Hong et al,15 whenmod-
eling data from two-arm studies, the correlation between treatment arms does not enter the likelihood and hence is not
included in the model. The relationships between the covariances are therefore not guaranteed, since a prior distribution
is not placed on the covariance matrix directly, and instead need to be modelled explicitly.
To model the bivariate second-order consistency, we extend the approach proposed by Lu and Ades17 to the bivariate
case by taking variance of the transitivity equation (5), which gives(
𝜏21kl 𝜏1kl𝜏2kl𝜌1kl,2kl
𝜏1kl𝜏2kl𝜌1kl,2kl 𝜏
2
2kl
)
=
(
var(𝜇1bli − 𝜇1bki) cov(𝜇1bli − 𝜇1bki, 𝜇2bli − 𝜇2bki)
cov(𝜇1bli − 𝜇1bki, 𝜇2bli − 𝜇2bki) var(𝜇2bli − 𝜇2bki)
)
(8)
leading to the following relationship between the variances for any three treatments (b, k, l) and for both outcomes
j = 1, 2:
𝜏2
𝑗kl = 𝜏
2
𝑗bk + 𝜏
2
𝑗bl − 2𝜌𝑗bk,𝑗bl𝜏𝑗bk𝜏𝑗bl ≤ (𝜏𝑗bk + 𝜏𝑗bl)
2, (9)
6 BUJKIEWICZ ET AL.
which gives the second-order consistency conditions (triangle inequalities)
|𝜏𝑗bl − 𝜏𝑗bk| ≤ 𝜏𝑗kl ≤ 𝜏𝑗bl + 𝜏𝑗bk. (10)
In addition, the following condition (derived in more detail in the Supplementary Materials) applies to the covariances:
𝜏1kl𝜏2kl𝜌1kl,2kl = 𝜏1bl𝜏2bl𝜌1bl,2bl + 𝜏1bk𝜏2bk𝜌1bk,2bk − 𝜏1bl𝜏2bk𝜌1bl,2bk − 𝜏1bk𝜏2bl𝜌1bk,2bl, (11)
which implies further constraints that are more complex than those in Equation (10).
To ensure that prior distributions for heterogeneous variance-covariance matrices are appropriate, ie, to maintain the
second-order consistency condition for any three treatments in the network, bivariate ancillary parameters are used,
extending the univariate model by Lu and Ades,17 allowing the between-studies variance-covariance matrices to be
represented as
(
𝜏21kl 𝜏1kl𝜏2kl𝜌1kl,2kl
𝜏1kl𝜏2kl𝜌1kl,2kl 𝜏
2
2kl
)
=
⎛⎜⎜⎜⎝
𝛾21k + 𝛾
2
1l − 2𝜉1k,1l𝛾1k𝛾1l
𝛾1k𝛾2k𝜉1k,2k − 𝛾1k𝛾2l𝜉1k,2l
−𝛾1l𝛾2k𝜉1l,2k + 𝛾1l𝛾2l𝜉1l,2l
𝛾1k𝛾2k𝜉1k,2k − 𝛾1k𝛾2l𝜉1k,2l
−𝛾1l𝛾2k𝜉1l,2k + 𝛾1l𝛾2l𝜉1l,2l 𝛾
2
2k + 𝛾
2
2l − 2𝜉2k,2l𝛾2k𝛾2l
⎞⎟⎟⎟⎠ , (12)
where the ancillary parameters 𝛾2
𝑗k and 𝛾
2
𝑗l are variances of two random effects 𝜁 jki and 𝜁 jli corresponding to treatment
arms k and l (for each outcome j = 1, 2), and 𝜉𝑗k,𝑗′l is their correlation coefficient. Prior distributions for the set of
between-studies standard deviations 𝜏 jkl for each outcome j and each pair of treatments k and l can be given by con-
structing a prior distribution for a covariance matrix Γ composed of the standard deviations 𝛾 jk and the correlations 𝜉𝑗k,𝑗′l
between the effects 𝜁 jki and 𝜁𝑗′li, for j, j ′ = 1, 2 and k, l = 1, … ,nt, where nt is the number of treatments in the net-
work. For the set of values of the elements of matrix Γ to give a resulting set of standard deviations 𝜏 jkl that satisfy the
second-order consistency rules (10) and (11), the matrix Γ has to be positive semidefinite. This is achieved using a sepa-
ration strategy with a Cholesky decomposition Γ = V1/2RV1/2, where V1/2 is a 2nt × 2nt diagonal matrix of the standard
deviations 𝛾11, 𝛾21, … , 𝛾1nt , 𝛾2nt and R is a positive semidefinite 2nt × 2nt matrix of correlations 𝜉𝑗k,𝑗′l (block matrix con-
sisting of nt × nt blocks that are of 2 × 2 dimension). Matrix R is represented as R = LTL with L being a 2nt × 2nt
upper triangular matrix. Further details on the derivation of this model and the construction of the prior distributions are
included in the Supplementary Materials.
4.1.3 Model 1c: bvNMAwith second-order consistency and similarity of the
ancillary parameters
To ensure second-order consistency of the treatment effects in the network, model 1b requires estimation of relatively
many parameters.Where data for each treatment k is only available from a limited number of studies, it may be difficult to
estimate the individual variances 𝛾21k. To overcome this issue, exchangeability of the ancillary variances may be assumed
by replacing individual prior distributions for these parameters with a common distribution
𝛾2
𝑗k ∼ N(0, v𝑗)I(0, ) and v𝑗 ∼ Γ(1.0, 0.01). (13)
4.1.4 Model 1d: bvNMA assuming homogeneity of the between-studies
variance-covariance matrix
When networks are sparse, instead of assuming similarity between the heterogeneity parameters, as in Equation (13),
homogeneity of the between-studies variance-covariance matrix can be assumed, which is a common assumption in the
mvNMA or the univariate NMA of multi-arm trials.26 The between-studies equation (4) then becomes(
𝜇1kli
𝜇2kli
)
∼ N
{(
d11l − d11k
d21l − d21k
)
, T =
(
𝜏21 𝜏1𝜏2𝜌
𝜏1𝜏2𝜌 𝜏
2
2 ,
)}
(14)
where 𝜇jkli is the random treatment effect difference between treatments k and l on outcome j in study i and dj1k is the
mean treatment effect difference between treatment k and the reference treatment 1 for outcome j, with dj11 = 0. A
prior distribution is placed on each basic parameter, as in Equation (7) of model 1a. A prior distribution is also placed on
the elements of the common between-studies variance-covariance matrix, ie, the between-studies standard deviations,
𝜏 j ∼ Unif(0, 2) and the correlation, 𝜌+12 ∼ Beta(1.5, 1.5).
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4.1.5 Study-level surrogacy criteria
When using the bvNMAmodels 1a to 1c to evaluate surrogate endpoints at the study level, within treatment contrast kl,
perfect surrogacy means that
𝜌1kl,2kl = ±1 and 𝜇1kli = 0 ⇔ 𝜇2kli = 0. (15)
These are criteria that may or may not be true and can be tested. They are equivalent to the surrogacy criteria suggested
by Daniels and Hughes,2 who stated that, in the linear surrogate relationship, the slopemeasures the association between
the treatment effects on the surrogate and clinical outcomes. In a perfect surrogate relationship, the slope is nonzero
and the conditional variance, of the treatment effect on the final outcome conditional on the effect on the surrogate
endpoint, is zero. This is equivalent to the left-hand side of the criterion (15). In addition, Daniels and Hughes discussed
the importance of zero intercept in the surrogacy criteria, explaining that if the surrogate relationship is perfect; then,
for a study with zero treatment effect on the surrogate endpoint, we would also expect zero treatment effect on the final
outcome. Otherwise, a candidate surrogate endpoint would not be a good surrogate as there would be, on average, a
treatment effect on the clinical outcome unexplained by a treatment effect on the surrogate endpoint. In our models,
the intercept is not explicitly present, but can be estimated from other parameters, 𝜆0 = d2kl − d1kl𝜌1kl,2kl𝜏2kl∕𝜏1kl. The
right-hand-side of criterion (15) can be tested by evaluating the intercept (to determine whether it is likely to be zero by,
eg, investigating the corresponding credible interval (CrI)). The details of the relationships between the surrogacy criteria
of our model and those set out by Daniels and Hughes are described in the Supplementary Materials.
This criterion describes the study-level surrogate relationships within the treatment contrasts. The network structure,
with the unique surrogate relationship for each treatment contrast, can help us to disentangle information about a sur-
rogate relationship for a particular treatment and to make better predictions, in particular when these relationships
are clearly distinct, as illustrated in the simulation study in Section 6. These individual (for each treatment contrast)
study-level surrogate relationships enable predicting the treatment effect on the final outcome from the treatment effect
measured on a surrogate endpoint in a new study investigating an existing treatment in a new population.
When evaluating surrogate endpoints with model 1d, as for models 1a to 1c, the random effects are assumed to fol-
low separate distributions for studies evaluating different treatment contrasts kl, but the between-studies correlations
and heterogeneity parameters are assumed to be the same across the treatment contrasts. In this case, perfect surrogacy
means that
𝜌 = ±1 and 𝜇1kli = 0 ⇔ 𝜇2kli = 0, (16)
which differs from the criteria for the models 1a to 1c with respect to the common correlation across the treatment con-
trasts. The strength of the association between the treatment effects on the surrogate endpoint and the final clinical
outcome will be the same across the treatment contrasts when using model 1d, as when using a pairwise meta-analysis
such as BRMA. However, assuming that the random effects for different treatment contrasts follow separate distribu-
tions in the bvNMA, we model these association patterns in more detail than when using BRMA. In addition, taking into
account the network structure of the data results in borrowing of strength across the treatment contrasts when evaluating
surrogate relationships.
As described above, the between-studies correlation equal to ±1 indicates perfect surrogacy. In practice, it is difficult to
quantify how large the correlation should be in order to consider the surrogate endpoint suitable to make the prediction.
Some authors claimed that a high level of association is required to demonstrate surrogacy. For example, Lassere et al in
their biomarker-surrogacy evaluation schema defined such high association by the square of the between-studies corre-
lation (or so-called adjusted R squared) above 0.6,27 and the German Institute of Quality and Efficiency in Health Care
requires high correlation with the lower limit of the 95% confidence interval (CI) above 0.85.28 Other authors emphasised
that the decision of whether the surrogate endpoint may be used to make the prediction of the clinical benefit should be
based on the balance between the strength of the surrogate relationship and the need for the decision to be made about
the effectiveness of the new treatment, eg, for regulatory purposes.29 Moreover, the strength (or weakness) of the surro-
gate relationship will manifest itself in the width of the predicted interval of the treatment effect on the final outcome.
A smaller value of the correlation will result in a larger interval and hence increased uncertainty about the regulatory or
clinical decision made based on such prediction. The implication of this is that perhaps we do not need criteria about the
correlation and instead we need only look at the predictions. The evaluation of the quality of predictions can be achieved
through a cross-validation procedure, which we discuss in Section 4.3.1.
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FIGURE 2 Example network diagram: data on effect of new treatment D only available in one new study and only measured on surrogate
endpoint (left) but not on the final outcome (right)
4.2 Bivariate NMAmodels with borrowing of strength across treatment contrasts
Models 1a to 1d describe study-level surrogate relationships within treatment contrasts and can be used to make predic-
tions of a treatment effect on the final outcome (from the treatment effect measured on surrogate endpoint) in a new
trial, which may investigate the treatment effects of an existing treatment but in different populations. It is assumed that
there will be at least one study in the network reporting the treatment effects on both outcomes allowing to make such
prediction. In the situation where we want to predict the treatment effect on the final outcome from the effect on the
surrogate endpoint in a new study evaluating a new treatment, there will be only this one study reporting the effect for
the new treatment and only on the surrogate endpoint. In this case, the models 1a to 1d will estimate the average effect
on the final outcome for the new treatment based solely on the prior distribution, because no data are available for the
effect of this treatment on the final outcome. For example, in the network depicted in Figure 2, if we select treatment
A as the reference treatment 1, then the average treatment effect for the new treatment D on the final outcome is equal
to d2CD = d2AD − d2AC and the estimate of the basic parameter d2AD would be based on the prior distribution only. As
a result, the estimate of the between-studies correlation 𝜌1CD,2CD will be based solely on the prior distribution. There-
fore, the predicted treatment effect on the final outcome from the treatment effect on the surrogate endpoint for the new
treatment will not be meaningful.
4.2.1 Models 2a to 2d: assuming exchangeability of treatments
To overcome the above issue, an exchangeability assumption can be made to allow for the relationships between the
average effects on the two outcomes to be similar across treatment contrasts. To achieve this for models 1a to 1d, instead
of placing a prior distribution on each basic parameter (Equation (7)), we need to add another level of hierarchy to the
models. The basic parameters dj1k, which are the effects relative to a common reference treatment, are not independent
and therefore cannot be assumed exchangeable. It is convenient to write, instead, themodel with a treatment-level effects
assuming that the pooled effects for each treatment arm k, 𝜃jk on the two outcomes j = 1, 2, are exchangeable and
correlated
d𝑗1k = 𝜃𝑗k − 𝜃𝑗1, (17)(
𝜃1k
𝜃2k
)
∼ N
((
𝜂1
𝜂2
)
,
1
2
(
𝜔21 𝜔1𝜔2𝜌t
𝜔1𝜔2𝜌t 𝜔
2
2
))
(18)
for k = 1, … ,nt.
The advantage of this approach is that the prior distributions for each pair (𝜃1k, 𝜃2k) are independent. The modelled
data Yjkli are the treatment effect differences; thus, the ancillary parameters 𝜃jk are not identifiable. However, we are
not interested in estimating these parameters, but in estimating the association between the average treatment effect
differences on the two outcomes, ie, djkl, j = 1, 2. The aforementioned formulae imply the association between the average
effects (
d1kl
d2kl
)
∼ N
{(
0
0
)
,
(
𝜔21 𝜔1𝜔2𝜌t
𝜔1𝜔2𝜌t 𝜔
2
2
)}
, (19)
k, l = 1, … ,nt (k ≠ l), cancelling out the mean values 𝜂j. Therefore, the mean values can be set arbitrarily to a
constant, eg, 𝜂j = 0. Prior distributions are placed on the elements of the covariance matrix, ie, 𝜔j ∼ Unif(0, 2) and
𝜌t+1
2 ∼ Beta(1.5, 1.5). Borrowing of strength across treatments by relating these parameters enables the model to predict
the effect of a new treatment on the final outcome, as in the network scenario in Figure 2.
The exchangeability model (17) to (18) for the effects across treatments is combined with models 1a to 1d, by replacing
the independent prior distributions on basic parameters (7), to form models 2a to 2d.
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4.2.2 Study- and treatment-level surrogacy criteria
As for models 1a to 1d, the perfect surrogate relationship between the treatment effects on the surrogate endpoint and
the final clinical outcome at the study level is described by criteria (15) and (16) for models 2a to 2c and 2d, respectively.
This study-level surrogate relationship between trials (or populations) is unique for each treatment contrast kl and it may
differ across these treatment contrasts. In addition to this, another level of surrogate relationship is described by models
2a to 2d, the treatment-level surrogacy. Such a surrogate relationship would be perfect if
𝜌t = ±1, and d1kl = 0 ⇔ d2kl = 0, (20)
where the first part describes the strength of this surrogate relationship and the second ensures that, in a perfect surrogate
relationship, zero average treatment effect difference between treatments k and l on the surrogate endpoint will imply
zero average treatment effect also on the final clinical endpoint for the same treatment contrast. This second criterion is
in fact equivalent to the exchangeability assumption in models 2a to 2d (the models assume zero intercept). This surro-
gate relationship allows prediction of the treatment effect on the final outcome from the treatment effect measured on a
surrogate endpoint in a new study investigating a new treatment.
4.3 Summary and discussion of models
Bivariate models for NMA described in this section differ in their specific assumptions about the heterogeneity between
studies and treatments. All components of the between-studies models for all models, 1a to 1d and 2a to 2d, are sum-
marised in Table 1. The models allow the correlations between the treatment effects on the surrogate and final endpoints
to vary to a different degree, and which model is applied in practice can be determined based on the available evidence
as well as the purpose of the model.
Models 1a to 1d are designed to evaluate study-level surrogacy patterns across different trials (which may investigate
the treatment effects in different populations) within each treatment contrast and make predictions of a treatment effect
on the final outcome in a new study investigating an existing treatment only, but perhaps in a new population. Models 2a
to 2d can be used to investigate treatment-level surrogacy and to make predictions of an effect of a new treatment on the
final clinical outcome from the effect measured on a surrogate endpoint in a new study investigating a new treatment.
In addition, models 2a to 2d can be used to estimate average effects of the new treatment on the final clinical outcome
relative to any of the treatments in the network, which is a unique feature of these models and cannot be achieved using
BRMA or models 1a to 1d. The choice between models 1a to 1d (and similarly between 2a to 2d) can be made based on
data availability and plausibility of their individual assumptions supported by investigating the model fit, eg, by the use
of deviance information criteria (DIC). The plausibility of the assumptions may be verified based on the inclusion criteria
for studies in the meta-analysis. Studies in similar populations are more likely to result in treatment effects satisfying the
consistency assumption and the second-order consistency assumption could be considered as a more strict assumption
TABLE 1 Components of each model in terms of the assumptions made about the between-studies variance-covariance matrix
Assumptions for the between-studies variance-covariance matrix
varying second- homogeneity prior
variance- order exchangeable of variance- distributions exchangeable
NMA -covariance consistency ancillary -covariance on basic treatments
model matrix Equations parameters matrix parameters Equations
Equation (4) (10) and (11) Equation (13) Equation (14) Equation (7) (17) and (18)
1a ✓ ✓
1b ✓ ✓ ✓
1c ✓ ✓ ✓ ✓
1d NA ✓ ✓
2a ✓ ✓
2b ✓ ✓ ✓
2c ✓ ✓ ✓ ✓
2d NA ✓ ✓
Abbreviations: NMA, network meta-analysis.
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about the trial populations being “especially” similar. The models reduce to the standard meta-analysis model for surro-
gate endpoints, such as the BRMA model (1) to (2), in the special data structure when there are only two treatments in
the network, as in the Supplementary Materials.
4.3.1 Strategies for model comparison
To make comparisons between the models, in the first instance, the between-studies correlations (as well as the mean
effects and the heterogeneity parameters) are obtained and compared across the models. Following this, predicted values
(and corresponding CrIs) of the treatment effects on the final outcome are compared to the observed estimates (and
corresponding CIs) in take-one-out cross-validation procedure. In one study at a time, the estimate of the treatment effect
on the final outcome Y2i is removed (and treated as missing at random), and then this treatment effect is predicted from
the treatment effect on the surrogate endpoint, conditional of the data on both outcomes from all the remaining studies
in the meta-analysis. The standard deviation of the predicted effect Ŷ2i is equal to
√
𝜎22i + var(?̂?2kli|Y1i, 𝜎1i,Y1(−i),Y2(−i)),
where Y1(− i) and Y2(− i) denote the data from the remaining studies without the validation study i (the treatment contrast
subscripts, present only in the NMA, have been dropped here).
The models were compared with respect to the predicted effects by investigating a number of statistics obtained from
each model, ie, (a) proportion of the CI of the observed estimate of the effect on the final outcome overlapping with the
CrI of the predicted effect, poverlap; (b) mean absolute difference between observed estimate of mean effect and predicted
mean effect on the final outcome across studies, |mobs − mpred|; (c) ratio of the width of intervals; the width of CrI of
the predicted effect to the width of the CI of the observed effect (the estimate), wpred∕wobs; (d) percentage reduction in
uncertainty measured by the width of the CrI of the predicted effect when using a mvNMA model, wNMA, compared
to the width of the CrI obtained from BRMA wBRMA, %red = 100wBRMA−wNMAwBRMA ; and (e) a new statistic measuring overall
performance of amodel giving a higher score formodels resulting in large poverlap with penalty for overly inflated predicted
interval 𝜋 = poverlapwpred∕wobs , which is always positive and less than one.
We apply the aforementioned procedures to the individual data sets (for the illustrative example in aCRC and for some
simulated toy data sets). In addition, we perform a simulation study, which is described in detail in Section 6.
5 RESULTS FOR ACRC DATA
In this section, we present results of applying all models (BRMA and bvNMA models 1a to 1d and 2a to 2d) to the aCRC
data, introduced in Section 2. Table 2 shows the between-studies correlations obtained from all the models applied to
the aCRC data. The correlations are the parameters of the primary interest as they tell us about the strength of the sur-
rogate relationships (see Sections 4.1.5 and 4.2.2). Additional results, the average effects, the heterogeneity parameters,
and the implied intercepts are included in the Supplementary Materials. When applying BRMA to data from all studies
(regardless of the treatment contrast), the between-studies correlation is negative, −0.67 (% CrI:−0.85, −0.41), as would
be expected when the surrogate outcome is a favourable event and the final outcome is an unfavourable event (treatment
increasing the odds of TR leads to reduced progression rate). As shown in the scatter plot in Figure 1, the distributions of
the treatment effects on the two outcomes, ie, log odds ratio of TR (surrogate endpoint) and log hazard ratio of PFS (final
outcome), representing their association patterns, vary across the treatment contrasts. When applying bvNMAmodels 1a
to 1c and 2a to 2c to the data, the between-studies correlations differ across treatment contrasts, with the highest correla-
tion obtained for treatment contrast AC (the results are presented only for those contrasts for which at least four studies
were available, the remaining results are included in the Supplementary Materials). When applying model 1b, assuming
second-order consistency and hence imposing additional constraints on the between-studies variance-covariance matri-
ces, the correlations were estimated with higher precision compared to those obtained from model 1a. Applying model
1c slightly inflated the CrIs of the correlations for some of the treatment contrasts (AC and BC) and minimally reduced
them for others (AB and BD) (compared to model 1b). The DIC value, shown in the right-hand-side column of the table,
is relatively high for model 1c indicating poor model fit. A similar pattern is observed across models 2a to 2c. When
assuming homogeneous variance-covariance matrices in models 1d and 2d, the between-studies correlations are high
and obtained with higher precision compared to the correlation obtained from BRMA. This is likely due to the borrowing
of strength across treatment contrasts, by adding information from the indirect comparisons. Based on the DIC criteria,
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TABLE 2 Between-studies correlations corresponding to the study-level surrogate relationship within each treatment contrast
for each model, 𝜌t is across-treatment correlations describing the treatment-level surrogacy obtained from the models allowing for
exchangeability, and deviance information criteria (DIC) values corresponding to each model fitted to aCRC data. Where only one
value is given for the between-studies correlation within a treatment contrast (models BRMA, 1d and 2d), the parameters are
common across the treatment contrasts
study-level surrogacy
model AB AC BC BD 𝜌t DIC
between-studies correlations
BRMA -0.67 (-0.85, -0.41) NA 43.9
bvNMA 1a -0.43 (-0.84, 0.16) -0.79 (-0.95, -0.46) -0.02 (-0.88, 0.88) -0.28 (-0.94, 0.65) NA 40.5
bvNMA 1b -0.61 (-0.9, -0.07) -0.79 (-0.95, -0.5) -0.3 (-0.91, 0.65) -0.25 (-0.89, 0.61) NA 41.8
bvNMA 1c -0.6 (-0.88, -0.11) -0.75 (-0.93, -0.44) -0.27 (-0.89, 0.66) -0.25 (-0.87, 0.6) NA 52.3
bvNMA 1d -0.75 (-0.9, -0.51) NA 39.8
bvNMA 2a -0.44 (-0.85, 0.13) -0.78 (-0.95, -0.47) -0.03 (-0.89, 0.88) -0.28 (-0.94, 0.67) -0.33(-0.92, 0.56) 39.5
bvNMA 2b -0.62 (-0.9, -0.09) -0.78 (-0.94, -0.48) -0.3 (-0.91, 0.66) -0.28 (-0.89, 0.59) -0.33 (-0.92, 0.57) 40.0
bvNMA 2c -0.6 (-0.89, -0.13) -0.73 (-0.93, -0.42) -0.25 (-0.89, 0.68) -0.25 (-0.87, 0.59) -0.33 (-0.91, 0.56) 56.6
bvNMA 2d -0.75 (-0.9, -0.5) -0.36 (-0.92, 0.52) 38.4
intercepts
BRMA -0.05 (-0.16, 0.06)
bvNMA 1a -0.28 (-0.42, -0.13) -0.03 (-0.18, 0.12) 0.05 (-1.26, 0.96) 0.12 (-0.32, 0.53)
bvNMA 1b -0.25 (-0.39, -0.11) -0.03 (-0.17, 0.11) 0.13 (-0.15, 0.42) 0.11 (-0.25, 0.48)
bvNMA 1c -0.25 (-0.38, -0.12) -0.04 (-0.18, 0.1) 0.12 (-0.15, 0.42) 0.11 (-0.13, 0.37)
bvNMA 1d -0.22 (-0.32, -0.11) -0.04 (-0.16, 0.08) 0.18 (0.07, 0.29) 0.16 (-0.03, 0.35)
bvNMA 2a -0.26 (-0.4, -0.11) -0.03 (-0.18, 0.11) 0.07 (-0.8, 0.95) 0.13 (-0.16, 0.44)
bvNMA 2b -0.23 (-0.37, -0.09) -0.03 (-0.17, 0.11) 0.12 (-0.16, 0.42) 0.12 (-0.14, 0.39)
bvNMA 2c -0.23 (-0.36, -0.1) -0.04 (-0.18, 0.09) 0.11 (-0.17, 0.41) 0.12 (-0.09, 0.35)
bvNMA 2d -0.2 (-0.31, -0.1) -0.04 (-0.16, 0.08) 0.16 (0.06, 0.27) 0.16 (-0.01, 0.33)
Note: A, chemotherapy alone; B, antiangiogenic treatments targeting vascular endothelial growth factor (anti-VEGF) therapies + chemotherapy;
C, epidermal growth factor receptor inhibitor (EGFRi) + chemotherapy; D, EGFRi + anti-VEGF therapies + chemotherapy
Abbreviations: BRMA, bivariate random effects meta-analysis; bvNMA, bivariate network meta-analysis.
models 1d, 2a, 2b, and 2d appear to fit the data best, although models 1a and 1b appear to have a comparable fit. Predic-
tion of the treatment effect on PFS (the final outcome) from the treatment effect on TR (the surrogate endpoint) for the
treatment contrast AE, for which only one study was available (new treatment scenario), was not possible for models 1a
to 1d, due to lack of data to estimate the surrogate relationship. Models 2a to 1d, assuming exchangeability of the aver-
age effects in each treatment arm across treatment contrasts, allowed us to make such a prediction. A forest plot of the
observed and predicted (fromBRMAandmodel 2d) effects on PFS is included in Figure 3 of the SupplementaryMaterials.
The advantage of using bvNMAmethods varied across the treatment contrasts, depending on the surrogate relationships
for each contrast. Table 2 also shows the across-treatment correlation 𝜌t indicating, consistently across models 2a to 2d, a
weak treatment-level surrogate relationship.
Table 3 shows statistics for model comparison, introduced in Section 4.3.1, for each treatment contrast where at least
four studies were available and across all the studies. For example, for the treatment contrast AB, the use of bvNMA
improved the precision of the predictions in terms of the point estimate, reducing the bias from 0.23 (obtained from
BRMA) to between 0.16 and 0.19. All bvNMA methods gave reduced predicted intervals for the treatment effect on PFS
(from the effect on TR) compared to those obtained from BRMA, between 12.2% and 17.1%. For contrasts AC and BC,
model 1a did not contribute to reduced uncertainty of predictions, but additional assumptions of second-order consis-
tency (models 1b and 2b) and additional borrowing of strength (models 1c and 2c) or assumption of homogeneity of
the correlations and heterogeneity parameters (models 1d and 2d) led to improved precision. The three observations in
contrast AC seen in the bottom right corner of the scatter plot of Figure 1 could be considered as potentially influential
observations. The impact of these observations on the correlations was assessed by sensitivity analysis. Results from the
sensitivity analysis of the data with these observations removed are presented in the Supplementary Materials. For the
treatment contrast BD, both sets of models 1a to 1b and 2a to 2b resulted in inflated predicted intervals. The final part of
Table 3 lists the average statistics across all treatments.
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TABLE 3 Comparison of models based on advanced colorectal cancer data
presented by treatment contrast for contrasts AB, AC, BC, and BD, and overall for
all data (for models 1a to 1d, the statistics were obtained for all the studies
excluding those in contrasts containing a single study)
poverlap |mobs − mpred| wpred∕wobs 𝝅 %red.
AB
BRMA 0.9 0.23 2.25 0.44 0
bvNMA 1a 0.9 0.19 1.87 0.53 16.61
bvNMA 1b 0.91 0.17 1.96 0.52 12.28
bvNMA 1c 0.9 0.18 1.84 0.54 17.09
bvNMA 1d 0.91 0.16 1.88 0.53 14.55
bvNMA 2a 0.9 0.19 1.89 0.52 15.71
bvNMA 2b 0.91 0.18 1.97 0.51 12.17
bvNMA 2c 0.9 0.18 1.85 0.53 16.88
bvNMA 2d 0.9 0.16 1.87 0.53 15.16
AC
BRMA 0.92 0.24 1.93 0.49 0
bvNMA 1a 0.94 0.24 1.92 0.51 0.24
bvNMA 1b 0.91 0.24 1.8 0.52 6.09
bvNMA 1c 0.88 0.25 1.7 0.53 11.06
bvNMA 1d 0.86 0.25 1.65 0.53 13.71
bvNMA 2a 0.94 0.24 1.92 0.51 0.1
bvNMA 2b 0.91 0.24 1.79 0.52 6.51
bvNMA 2c 0.87 0.25 1.69 0.53 11.59
bvNMA 2d 0.85 0.25 1.64 0.53 14.42
BC
BRMA 0.97 0.17 2.3 0.46 0
bvNMA 1a 0.99 0.09 3.1 0.4 -28.54
bvNMA 1b 0.96 0.09 2.13 0.5 8.07
bvNMA 1c 0.95 0.09 1.84 0.55 19.53
bvNMA 1d 0.95 0.1 1.94 0.52 14.91
bvNMA 2a 0.99 0.08 2.98 0.42 -23.21
bvNMA 2b 0.96 0.08 2.08 0.51 10.21
bvNMA 2c 0.95 0.08 1.75 0.58 23.11
bvNMA 2d 0.96 0.09 1.93 0.53 15.16
BD
BRMA 0.82 0.3 1.89 0.45 0
bvNMA 1a 1 0.23 4.34 0.25 -128.76
bvNMA 1b 1 0.23 3.7 0.29 -94.61
bvNMA 1c 0.84 0.25 1.74 0.51 7.59
bvNMA 1d 1 0.14 1.78 0.58 5.29
bvNMA 2a 1 0.21 3.46 0.31 -83.09
bvNMA 2c 0.83 0.23 1.64 0.52 12.2
bvNMA 2d 1 0.13 1.73 0.6 8.07
All
BRMA 0.91 0.24 2.02 0.48 0
bvNMA 1a 0.9 0.19 2.36 0.45 -23.74
bvNMA 1b 0.89 0.19 2.2 0.46 -16.79
bvNMA 1c 0.86 0.2 1.7 0.51 11.27
bvNMA 1d 0.86 0.18 1.69 0.51 11.67
bvNMA 2a 0.94 0.2 2.34 0.47 -20.36
bvNMA 2b 0.93 0.2 2.14 0.49 -10.02
bvNMA 2c 0.89 0.2 1.73 0.54 12.75
bvNMA 2d 0.9 0.19 1.73 0.54 12.76
Abbreviations: BRMA, bivariate random effects meta-analysis; bvNMA, bivariate network
meta-analysis.
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6 SIMULATION STUDY
6.1 Methods
To compare the performance of the methods, data were simulated under four different assumptions. Specifically, we
simulated data where the surrogate pattern across all studies and treatments differed from the patterns within treatment
contrasts. The treatment effects on two outcomes were simulated from the bvNMA model 1a. Four sets of network data
were generated, each consisting of 45 studies, three treatments (A, B, and C), and three treatment contrasts (AB, BC, and
AC) with 15 studies per contrast, under different scenarios. A representative data set from each scenario is illustrated in
Figure 3.
FIGURE 3 Scatter plots of the artificial data simulated under scenario 1 (top left), scenario 2 (top right), scenario 3 (bottom left), and
scenario 4 (bottom right) and network diagram corresponding to the structure of data for both scenarios [Colour figure can be viewed at
wileyonlinelibrary.com]
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Scenario 1 shows weak study-level surrogacy when ignoring treatment contrasts but strong study-level surrogacy
within each treatment contrast. It uses the following parameters: dAB = (1, 2), dBC = (2, 1), dAC = (3, 3); 𝜎jAB(AC,BC)i ∼
Unif(0.15, 0.25), j=1,2; 𝜌wABi = 𝜌wBCi = 𝜌wACi = 0.6; 𝜏1AB = 0.3, 𝜏1BC = 𝜏1AC = 0.6, 𝜏2BC = 0.3, and 𝜏2AB = 𝜏2AC =
0.6; 𝜌AB = 𝜌AC = 𝜌BC = 0.9.
Scenario 2 shows strong study-level surrogacy both when ignoring treatment contrasts and within each treatment
contrast, with the following parameters: dAB = (1, 1), dBC = (2, 2), dAC = (3, 3); 𝜎jAB(AC,BC)i ∼ Unif(0.05, 0.15), j= 1,2;
𝜌wABi = 𝜌wBCi = 𝜌wACi = 0.98; 𝜏1AB = 0.2, 𝜏1BC = 0.25, 𝜏1AC = 0.3, 𝜏2AB = 0.3, 𝜏2BC = 0.25, and 𝜏2AC = 0.2;
𝜌AB = 𝜌AC = 𝜌BC = 0.9.
Scenario 3 shows no study-level surrogacy bothwhen ignoring treatment contrasts andwithin each treatment contrast,
with the following parameters: dAB = (1, 2), dBC = (2, 1), and dAC = (3, 3); 𝜎jAB(AC,BC)i ∼ Unif(0.15, 0.25), j= 1,2;
𝜌wABi = 𝜌wBCi = 𝜌wACi = 0.6; 𝜏1AB = 𝜏1BC = 𝜏1AC = 𝜏2BC = 𝜏2AB = 𝜏2AC = 0.4; 𝜌AB = 𝜌AC = 𝜌BC = 0.25.
Scenario 4 shows strong study-level surrogacy when ignoring treatment contrasts but no study-level surrogate rela-
tionship within each treatment contrast. It uses the following parameters: dAB = (1, 1), dBC = (2, 2), and dAC = (3, 3);
𝜎jAB(AC,BC)i ∼ Unif(0.05, 0.15), j= 1,2; 𝜌wABi = 𝜌wBCi = 𝜌wACi = 0.6; 𝜏1AB = 0.2, 𝜏1BC = 0.25, 𝜏1AC = 0.3, 𝜏2AB = 0.3,
𝜏2BC = 0.25, and 𝜏2AC = 0.2; 𝜌AB = 𝜌AC = 𝜌BC = 0.25.
The data were simulated from model 1a for simplicity, to allow for generating very clear and simple scenarios.
Although by simulating frommodel 1a we do not explicitly assume second-order consistency, this does not mean that the
assumption is not satisfied for the simulated data and, in fact, the parameters we choose are such that the second-order
consistency is satisfied, which is shown in Section 10 of the Supplementary Materials.
For each scenario, 1000 data sets were simulated and all models were fitted to these data. Between-studies correlations
for each treatment contrast were monitored for their estimated values, coverage, root mean squared error (RMSE), and
Monte Carlo error. Subsequently, another simulation study was conducted aiming to evaluate the methods when used for
predicting the treatment effect on the final outcome from the effect measured on the surrogate endpoint. The same four
scenarios were used and the predictions were made assuming that the first simulated study, for each contrast, in turn,
was a new study (in a similar manner as in the cross-validation procedure, as described in Section 4.3.1, but only for three
studies in each simulated data set).
6.2 Results
Table 4 showsmean values of estimated between-studies correlations, correspondingmeanwidth of theCrI, coverage, and
RMSE for each scenario and all NMAmodels. Only mean of the correlation and mean width of CrI are shown for BRMA
and NMA models 1d and 2d as these methods do not estimate individual correlations for each contrast, and hence, the
coverage and the RMSE were not applicable. Table 5 shows results from the simulation study evaluating the predictions
of the treatment effect on the final outcome from the treatment effect on the surrogate endpoint. The values presented
are the coverage and the RMSE for the true effects on the final outcome 𝜇2kli for study i, which is the first study out of
15 studies simulated per treatment contrast (studies 1, 16, and 31). The last column for each contrast corresponds to the
ratio between the width of the predicted interval from each model to the width of the interval obtained from BRMA.
6.2.1 Scenario 1
As shown in the top part of Table 4, the between-studies correlation obtained fromBRMA (across all studies) was not very
high, on average 0.55 (mean width of 95% CrI (wCrI): 0.42). Bivariate NMA with the covariance matrix varying across
treatment contrasts modelled the data in more detail and revealed stronger correlation between the treatment effects
on the two outcomes within the treatment contrasts, on average 0.73 (0.70) for treatment contrast AB, 0.74 (0.68) for
BC, and 0.82 (0.43) for AC when using model 1a. Placing additional constraints on the covariance matrix by assuming
second-order consistency inmodels 1b and 1c reduced uncertainty around the correlations.Model 1d resulted in common
correlations obtained with the highest precision, resulting from the assumption of homogeneity of the correlations and
hence much larger data contributing to these estimates. However, model 1d did not take into account the differences
in the between-studies variances across the treatment contrasts, in contrast to models 1a to 1c. Similar patterns can be
observed for models 2a to 2d.
The coverage was high except for models 1b, 1c, 2b, and 2c for the correlation corresponding to the contrast BC. This
was likely due to the correlation being underestimated (more so than by models 1a and 2a) but obtained with higher
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TABLE 4 Results of the simulation study showing the between-studies correlations 𝜌kl for each treatment contrast (for bivariate
random effects meta-analysis (BRMA) and models 1d and 2d only a single overall correlation available), the corresponding widths of
the credible intervals (wCrIs), coverage, and root mean squared error (RMSE). 99% of simulations resulted in Monte Carlo
error<0.02 in scenario 1, 99.7% in scenario 2, more than 99.75% in scenario 3 and 100% in scenario 4
AB BC AC
mean mean mean
model 𝝆kl / wCrI coverage RMSE 𝝆kl / wCrI coverage RMSE 𝝆kl / wCrI coverage RMSE
scenario 1: true correlations 𝜌kl = 0.9
BRMA 0.55 / 0.42
bvNMA 1a 0.73 / 0.70 0.93 0.23 0.74 / 0.68 0.94 0.22 0.82 / 0.43 0.96 0.13
bvNMA 1b 0.77 / 0.58 0.95 0.19 0.72 / 0.62 0.88 0.22 0.84 / 0.40 0.98 0.11
bvNMA 1c 0.74 / 0.61 0.92 0.21 0.69 / 0.65 0.80 0.25 0.82 / 0.42 0.94 0.13
bvNMA 1d 0.77 / 0.30
bvNMA 2a 0.73 / 0.70 0.93 0.23 0.74 / 0.68 0.94 0.22 0.82 / 0.44 0.96 0.13
bvNMA 2b 0.77 / 0.57 0.95 0.19 0.72 / 0.61 0.88 0.22 0.84 / 0.38 0.97 0.11
bvNMA 2c 0.74 / 0.61 0.92 0.21 0.69 / 0.65 0.80 0.25 0.82 / 0.42 0.94 0.13
bvNMA 1d 0.77 / 0.30
scenario 2: true correlations 𝜌kl = 0.9
BRMA 0.99 / 0.02
bvNMA 1a 0.80 / 0.47 0.94 0.15 0.80 / 0.46 0.92 0.16 0.80 / 0.47 0.93 0.16
bvNMA 1b 0.82 / 0.40 0.95 0.13 0.80 / 0.47 0.94 0.16 0.81 / 0.41 0.93 0.14
bvNMA 1c 0.79 / 0.44 0.88 0.15 0.76 / 0.51 0.84 0.19 0.79 / 0.44 0.88 0.16
bvNMA 1d 0.82 / 0.22
bvNMA 2a 0.80 / 0.47 0.94 0.15 0.80 / 0.46 0.92 0.16 0.80 / 0.47 0.93 0.16
bvNMA 2b 0.82 / 0.40 0.95 0.13 0.80 / 0.47 0.94 0.16 0.81 / 0.41 0.93 0.14
bvNMA 2c 0.79 / 0.44 0.89 0.15 0.76 / 0.51 0.85 0.19 0.79 / 0.43 0.88 0.16
bvNMA 2d 0.82 / 0.22
scenario 3: true correlations 𝜌kl = 0.25
BRMA 0.42 / 0.49
bvNMA 1a 0.16 / 1.08 0.98 0.27 0.16 / 1.07 0.97 0.27 0.16 / 1.07 0.97 0.27
bvNMA 1b 0.19 / 1.04 0.98 0.26 0.16 / 1.01 0.98 0.24 0.19 / 1.03 0.98 0.25
bvNMA 1c 0.15 / 1.01 0.97 0.27 0.14 / 0.97 0.96 0.25 0.15 / 1.00 0.96 0.27
bvNMA 1d 0.22 / 0.66
bvNMA 2a 0.16 / 1.08 0.98 0.27 0.16 / 1.07 0.97 0.27 0.16 / 1.07 0.97 0.27
bvNMA 2b 0.19 / 1.04 0.98 0.26 0.18 / 1.01 0.98 0.24 0.19 / 1.03 0.98 0.25
bvNMA 2c 0.15 / 1.01 0.97 0.27 0.14 / 0.97 0.96 0.25 0.15 / 1.01 0.96 0.27
bvNMA 2d 0.22 / 0.66
scenario 4: true correlations 𝜌kl = 0.25
BRMA 0.92 / 0.09
bvNMA 1a 0.17 / 1.02 0.98 0.25 0.17 / 1.00 0.97 0.25 0.17 / 1.02 0.96 0.26
bvNMA 1b 0.19 / 0.98 0.98 0.24 0.18 / 0.98 0.98 0.23 0.19 / 0.98 0.97 0.25
bvNMA 1c 0.17 / 0.95 0.96 0.25 0.15 / 0.92 0.96 0.23 0.16 / 0.95 0.95 0.25
bvNMA 1d 0.21 / 0.62
bvNMA 2a 0.17 / 1.02 0.98 0.25 0.17 / 1.00 0.97 0.25 0.17 / 1.02 0.96 0.26
bvNMA 2b 0.19 / 0.98 0.98 0.24 0.18 / 0.98 0.98 0.23 0.19 / 0.98 0.97 0.25
bvNMA 2c 0.17 / 0.95 0.96 0.25 0.15 / 0.92 0.96 0.23 0.16 / 0.95 0.95 0.25
bvNMA 2d 0.21 / 0.62
Abbreviations: bvNMA, bivariate network meta-analysis.
precision, compared to models 1a and 2a where the coverage was high, due to the second-order consistency assumption
enforcing additional constraints on the covariances.
There may be a number of potential mechanisms for the reduced coverage of the correlation (seen in models 1b, 1c,
2b, and 2c and in particular for contrast BC). The between-studies correlations are usually underestimated because of a
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TABLE 5 Results of the simulation study showing the performance of the models in terms of predicting the
treatment effect on the final outcomes from the effect measured on surrogate endpoint in a new study. Presented
values are coverage and root mean squared error (RMSE) for the true effects on the final outcome and the CrI width
ratio (wCrIr); the ratio between the width of the predicted interval from each model to the width of the interval
obtained from bivariate random effects meta-analysis (BRMA)
AB BC AC
model coverage RMSE wCrIr coverage RMSE wCrIr coverage RMSE wCrIr
scenario 1
BRMA 0.99 0.72 0.99 0.72 1.00 1.10
bvNMA 1a 0.99 0.41 0.57 0.98 0.42 0.57 0.98 0.19 0.27
bvNMA 1b 0.98 0.41 0.51 0.97 0.42 0.51 1.0 0.18 0.29
bvNMA 1c 0.97 0.42 0.48 0.96 0.43 0.48 0.99 0.19 0.27
bvNMA 1d 0.95 0.44 0.43 0.95 0.45 0.43 0.98 0.26 0.45
scenario 2
BRMA 0.93 0.19 0.95 0.18 0.98 0.15
bvNMA 1a 0.98 0.19 1.15 0.97 0.18 1.16 0.98 0.15 0.92
bvNMA 1b 0.96 0.19 1.04 0.96 0.18 1.05 0.99 0.15 0.96
bvNMA 1c 0.96 0.20 1.01 0.95 0.19 1.01 0.98 0.15 0.92
bvNMA 1d 0.93 0.20 0.90 0.94 0.19 0.90 0.99 0.15 0.92
scenario 3
BRMA 1.0 0.57 1.0 0.59 0.95 1.07
bvNMA 1a 0.97 0.40 0.51 0.97 0.42 0.51 0.98 0.40 0.52
bvNMA 1b 0.97 0.40 0.50 0.98 0.42 0.50 0.98 0.39 0.52
bvNMA 1c 0.96 0.40 0.45 0.96 0.42 0.45 0.97 0.39 0.47
bvNMA 1d 0.98 0.39 0.47 0.97 0.41 0.47 0.99 0.39 0.48
scenario 4
BRMA 0.95 0.35 0.95 0.35 0.97 0.30
bvNMA 1a 0.97 0.31 0.96 0.98 0.31 0.96 0.98 0.25 0.83
bvNMA 1b 0.96 0.30 0.88 0.97 0.31 0.89 0.98 0.25 0.83
bvNMA 1c 0.95 0.30 0.82 0.96 0.31 0.83 0.97 0.25 0.76
bvNMA 1d 0.95 0.30 0.75 0.95 0.31 0.75 0.97 0.25 0.76
Abbreviations: bvNMA, bivariate network meta-analysis.
relatively small sample of studies inmeta-analysis. Assuming second-order consistency, in addition to random effects and
the first-order consistency assumption, is likely to result in further borrowing of information. This may lead to increased
precision of the estimated correlations and/or more shrinkage of the true effects (towards the mean effects) on both
outcomes, which may reduce the mean value of the correlation. Change in coverage will be a result of a balance between
bias and precision. For example, for contrasts AB and AC, model 1b gave more precise correlations, which could result
in reduced coverage, but the mean correlations were closer to the true values resulting in increased coverage compared
to model 1a. However, for contrast BC, the correlation was obtained with higher precision and the point estimate moved
away from the true value increasing the bias and thus led to reduced coverage. It is difficult to compare the results from
models 1a and 1b directly because they use different sets of prior distributions for the correlations. Moreover, the choice
of the ordering of the treatment contrasts may impact on the prior distributions in model 1b, which used a Cholesky
decomposition.
The top part of Table 5 shows results from the simulation study evaluating the predictions of the treatment effect on the
final outcome from the treatment effect on the surrogate endpoint in scenario 1. Large coverage for each contrast indicated
perhaps large uncertainty. However, the bias expressed as RMSE was reduced when using NMA models compared to
BRMA. The uncertainty was also largely reduced when using NMAmodels compared to BRMA, between 43% and 73%.
6.2.2 Scenario 2
The second section of Table 4 shows the between-studies correlations for the data simulated under scenario 2. The overall
mean correlation obtained from BRMA is high, ie, 0.99 (wCrI: 0.02). Bivariate NMAwith the variance-covariance matrix
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varying across treatment contrasts resulted in high correlations within each treatment contrast, but obtained with much
higher uncertainty compared to BRMA, due to fewer data points within each treatment contrast. The coverage was low
for all correlations obtained from models 1c and 2c, likely also due to the correlation being underestimated to a higher
degree compared to models 1a, 1b, 2a, and 2b.
The second section of Table 5 shows results from the simulation study evaluating the predictions. There was not much
improvement in predictions when using NMAmodels, as BRMA gave precise predictions already, due to the very strong
surrogacy patterns across all data. The width of the predicted interval varied across models and treatment contrasts
ranging between being inflated by up to 15% or reduced by up to 10%.
6.2.3 Scenario 3
The third section of Table 4 shows the average between-studies correlations for the data simulated under scenario 3, which
indicate the lack of surrogate relationship at the study level overall (BRMA) where the mean correlation was 0.42 and
within each treatment contrast (NMAmodels)where correlationsweremuch smaller and obtainedwith large uncertainty.
Coverage was high due to the large uncertainty around the estimates of the correlations. The results were comparable
across models, perhaps with reduced uncertainty around the correlations when using models 1d and 2d.
The third section of Table 5 shows results of the simulation investigating predictions in scenario 3. A large improvement
was noted in terms of reduced bias and uncertainty of predictions when using NMA models compared to BRMA where
the predicted intervals were reduced by approximately 50%.
6.2.4 Scenario 4
The bottom section of Table 4 shows the average between-studies correlations for the data simulated under scenario 4. The
mean correlation obtained from BRMA is very high, ie, 0.92 (wCrI: 0.09). However, as expected, the correlations within
each contrast indicated no surrogate relationship at the study-level within these contrasts. Similarly, as in scenario 3,
the results were comparable across models, but with reduced uncertainty around the correlations when using models 1d
and 2d.
As shown in the bottom part of Table 5, the improvement in predictions was less pronounced in scenario 4, but still
noticeable, with the width of the CrI being reduced between 4% and 25%.
6.3 Discussion of the simulations
To help the reader understand better the heterogeneity patterns in each data scenario and their implications on the mea-
sures of surrogate relationships, we simulated and analysed single data sets under very similar scenarios and presented
detailed results of these analyses in the Supplementary Materials. We presented there also an additional scenario, with
a mixed surrogacy pattern (strong and weak) across treatment contrasts to illustrate better (compared to the illustrative
example in aCRC) how the proposedmethods differentiate between the surrogate relationships across treatment contrasts
and hence allow for identifying treatment contrasts with high surrogacy patterns.
The aforementioned simulation study investigated data scenarios where a number of trials exist for each treatment con-
trast. This illustrates well the use of the bvNMAmodels to investigate the study-level surrogacywithin treatment contrasts
and for making predictions of the treatment effect on the final outcome from the treatment effect on the surrogate end-
point in a new study investigating an existing treatment in the network but in a new population (eg, a different country).
As discussed in Section 4.2, bvNMAmodels 2a to 2d can be used to make such predictions for a new treatment when no
data are available yet for the effect of this treatment on the final outcome. We investigated this through an initial simu-
lation study and, although such predictions can be made, eg, for treatment D as illustrated in Figure 2, these predictions
are obtained with large uncertainty. Further investigation in larger networks led to not only the same conclusions but
indicated that the predictions are likely to be comparable or more uncertain compared to those obtained from BRMA.
Nevertheless, bvNMA models 2a to 2d are still valuable as they can be used to estimate the average effects of the new
treatment on both outcomes relative to any treatment in the network, which is not achievable by BRMA and bvNMA
models 1a to 1d can only estimate these effects on the surrogate endpoint (when nomeasurement on the final clinical out-
come is available). This quality may be useful in a regulatory or health technology assessment decision-making context,
in particular at the early stages of the drug development process. Further research is required to investigate the properties,
assumptions, and application of models 2a to 2d.
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7 DISCUSSION
We have developed bivariate network meta-analytic models for surrogate endpoint evaluation to allow for more detailed
modelling of surrogate relationships at the study level (within each treatment contrast) and at the treatment level. This
methodology canhelp to disentangle information about surrogate relationships in data scenarioswhere such relationships
vary across treatment contrasts and are distinct in comparison with an association pattern across treatments. Two types of
surrogacy have been described by the models, ie, study-level surrogacy for a given treatment contrast and treatment-level
surrogacy. The models allow analysts to make predictions of the treatment effect on the final clinical outcome from the
observed effect on a surrogate endpoint in a new study investigating the effectiveness of an existing treatment in a new
setting or a new treatment.
There are some limitations to themodels presented here. For simplicity, we focused on themodels for data from two-arm
studies. The methods can be extended to model multi-arm trial data in a similar manner as in Achana et al.12 Another
limitation is related to the prior distribution for the ancillary variance-covariance matrix in model 1b, introduced to allow
for the second-order consistency constraints. It was based on the Cholesky decomposition, which results in the prior
distributions for the between-studies correlations being dependent on the ordering of the treatments in the network.
We carried out a sensitivity analysis by changing the ordering of treatments in the illustrative example in aCRC; the
results remained very similar to those obtained from the main analysis. Alternative prior distributions could also be
constructed for the covariance matrix, eg, using the separation strategy by spherical decomposition10,12,17 or an inverse
Wishart prior distribution; however, a number of authors found that Wishart priors had an influential impact on the
posterior distribution.6,10,30
The choice of the model parameterisation and a prior distribution can be difficult to make. The decision about the final
model can be made based on DIC. In addition, plausibility of the assumptions of individual models should be considered.
For example, when choosing between models 1a and 1b, plausibility of the second-order consistency assumption needs
to be verified. For the second-order consistency assumption, we are requiring not only first order but also second-order
moments to “add up around loops” and so this stronger assumption could also be thought more plausible in situations
where the trial populations are “especially” similar. In addition, to aid decisions about themodel choice, the second-order
consistency assumption can also be checked by following a procedure similar to the one used in Section 10 of the
Supplementary Materials.
Another sensitivity analysis was carried out to investigate the impact of potentially influential observations, whichwere
detected by visually assessing the scatter plots. More formal approaches to detecting outlying observations are available,
developed by Zhang et al31 and Viechtbauer el al,32 but were beyond the scope of this paper.
Scarcity of datamay also present a problem in fitting themodels. For estimation of the surrogate relationshipswithin the
treatment contrasts, a relatively large number of trials per treatment contrast is needed, whereas for the treatment-level
surrogacy, a relatively large number of treatments needs to be included in the network.
The models presented in this paper were developed to describe the surrogate relationships between the average effects
at the study level and at the treatment level, but not at the individual level. Further work will be carried out to extend
the methods to bivariate IPD NMA to incorporate the individual-level surrogacy as in the works of Buyse et al3 and
Burzykowski et al.4
We believe that the models have great potential for making improvements in the research area of surrogate endpoint
evaluation. In our example in aCRC, the models allowed us to disentangle information on a relatively strong study-level
surrogate relationship between treatment effects on TR and PFS for the treatment contrast of EGFRi with chemotherapy
vs. chemotherapy alone from a set of treatments with suboptimal overall surrogacy relationship. Moreover, in medical
decisionmaking,wheremultiple comparisons of newhealth technologies against different comparators play an important
role, NMA is a valuable tool in obtaining average effects across all treatment contrasts in the network of treatments. In a
similar way, our proposed methodology can be used to predict the effect of a new treatment on the final clinical outcome
against any comparator in the network. In conclusion, we developed a newmeta-analytic method for surrogate endpoint
evaluation that allows modelling of surrogate relationships in greater detail.
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